sellWeak10b5-1 plan
Lewis William sold $1.8M of INSM
Chair and CEO at INSMED Inc. 25,580 shares at an average of $69.91, traded Dec 19, 2024, filed Dec 20, 2024.
Warning score
15Value
$1.8M
25,580 shares
Holdings after
233,924
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-24-052229, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2024 | MOption exercise Common Stock10b5-1 | +18,750 | $22.76 | $427k | 403,710 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stock10b5-1 | -13,162 | $69.65 | $917k | 390,548 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stock10b5-1 | -5,588 | $70.52 | $394k | 384,960 | Dec 20, 2024 |
| Dec 19, 2024 | MOption exercise Common Stockindirect: By the Katie Procter Dynasty Trust10b5-1 | +6,830 | $10.85 | $74k | 240,754 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stockindirect: By the Katie Procter Dynasty Trust10b5-1 | -5,240 | $69.71 | $365k | 235,514 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stockindirect: By the Katie Procter Dynasty Trust10b5-1 | -1,590 | $70.61 | $112k | 233,924 | Dec 20, 2024 |
| Dec 19, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -18,750 | $0.00 | $0 | 112,500 | Dec 20, 2024 |
| Dec 19, 2024 | MOption exercise Stock Option (right to buy)derivativeindirect: By the Katie Procter Dynasty Trust10b5-1 | -6,830 | $0.00 | $0 | 232,290 | Dec 20, 2024 |
Related signals
Other insiders at INSMED Inc and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 15Weak | sell10b5-1 | INSM INSMED Inc | Lewis William Chair and CEO | $1.9M | 25,580 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.